Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1757-2215
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer ; volume:14 ; number:1 ; day:20 ; month:5 ; year:2021 ; pages:1-9 ; date:12.2021
Journal of ovarian research ; 14, Heft 1 (20.5.2021), 1-9, 12.2021
- Creator
-
Parvathareddy, Sandeep Kumar
Siraj, Abdul K.
Masoodi, Tariq
Annaiyappanaidu, Padmanaban
Al-Badawi, Ismail A.
Al-Dayel, Fouad
Al-Kuraya, Khawla S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13048-021-00827-8
- URN
-
urn:nbn:de:101:1-2021091818441894179768
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Parvathareddy, Sandeep Kumar
- Siraj, Abdul K.
- Masoodi, Tariq
- Annaiyappanaidu, Padmanaban
- Al-Badawi, Ismail A.
- Al-Dayel, Fouad
- Al-Kuraya, Khawla S.
- SpringerLink (Online service)
Other Objects (12)
Cyclin-dependent kinases
Cyclin-dependent kinases and rare developmental disorders
Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia
Cyclin-dependent kinase 5 mediates pleiotrophin-induced endothelial cell migration
Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer
TRAILblazing: cyclin-dependent kinase 9 (CDK9) as target in pancreatic cancer
Mitotic p21Cip1/CDKN1A is regulated by cyclin-dependent kinase 1 phosphorylation
Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling
Biochemical characterization of the human Cyclin-dependent kinases Cdk7 and Cdk10
Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs) : bench to bedside
A cyclin-dependent kinase-mediated phosphorylation switch of disordered protein condensation
Cyclin-dependent kinases
Cyclin-dependent kinases and rare developmental disorders
Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia
Cyclin-dependent kinase 5 mediates pleiotrophin-induced endothelial cell migration
Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer
TRAILblazing: cyclin-dependent kinase 9 (CDK9) as target in pancreatic cancer
Mitotic p21Cip1/CDKN1A is regulated by cyclin-dependent kinase 1 phosphorylation
Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling
Biochemical characterization of the human Cyclin-dependent kinases Cdk7 and Cdk10
Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs) : bench to bedside
A cyclin-dependent kinase-mediated phosphorylation switch of disordered protein condensation
Cyclin-dependent kinases
Cyclin-dependent kinases and rare developmental disorders
Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia
Cyclin-dependent kinase 5 mediates pleiotrophin-induced endothelial cell migration
Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer
TRAILblazing: cyclin-dependent kinase 9 (CDK9) as target in pancreatic cancer
Mitotic p21Cip1/CDKN1A is regulated by cyclin-dependent kinase 1 phosphorylation
Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling
Biochemical characterization of the human Cyclin-dependent kinases Cdk7 and Cdk10
Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs) : bench to bedside